Search Results

11 - 20 of 35 items :

  • Emergency Medicine and Intensive-Care Medicine x
Clear All
Stem Cell Mobilization and Harvesting Failure in Case of Heavily Pretreated Patients

REFERENCES 1. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cell matter? Blood . 2001;98:2900-2908. 2. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood . 1997; 89:2233-2258. 3. Jillella AP, Ustun C. What is the optimum number of CD34 peripheral blood stem cells for an autologous transplant? Stem Cells Dev . 2004;13:598-606. 4. Vose JM, Ho AD, Coiffier B, et al. Advances in mobilization for the

Open access
Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients

REFERENCES 1. Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica . 2014;99:408-416. 2. Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant . 2014;49:865-872. 3. Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non

Open access
Leukemia with Plasma Cells — Case Report

, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia . 2008;22:1044-1052. 5. Gertz MA, Buadi FK. Plasma cell leukemia. Haematologica . 2010;95:705-707. 6. Hanbali A, Alrajeh A, Rasheed W. Plasma cell leukemia mimicking hairy cell leukemia. Hematol Oncol Stem Cell Ther . 2015;8:91-92. 7. Van de Donk NWCJ, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood . 2012;120:2376-2389. 8. Jakab Sz, Lazar E, Benedek I Jr., et al. New Treatment Methods in Multiple Myeloma. Journal of

Open access
Double Autologous Stem Cell Transplantation in a Case of Non-secretory Multiple Myeloma

References 1. Attal M, Harouseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide imporves survival in patinets with multiple myeloma. Blood . 2006;108:3289-3294. 2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemotherapy for multiple myeloma: Final results of a phase III US intergroup trail S9321. J Clin Oncol . 2006;24:929-936. 3. van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood . 2014;124:328-333. 4. Koreth J, Clutler CS

Open access
Therapeutic Angiogenesis for Severely Ischemic Limbs — from Bench to Bedside in Acute Vascular Care

.01.005. 13. Gilliland C, Shah J, Martin JG, Miller MJ Jr. Acute Limb Ischemia. Tech Vasc Interv Radiol. 2017;20:274-280. doi: 10.1053/j.tvir.2017.10.008. 14. Compagna R, Amato B, Massa S, et al. Cell Therapy in Patients with Critical Limb Ischemia. Stem Cells Int. 2015;2015:931420. doi: 10.1155/2015/931420. 15. Simons JP, Goodney PP, Nolan BW, et al. Failure to achieve clinical improvement despite graft patency in patients undergoing infrainguinal lower extremity bypass for critical limb ischemia. J Vasc Surg. 2010;51:1419-1424. doi: 10.1016/j.jvs.2010

Open access
New Treatment Methods in Multiple Myeloma

dexamethasone as induction pre-transplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood . 2012;120:1589-1596. 5. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m 2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM95-02 randomized trial. Blood . 2002;99:731-735. 6. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over

Open access
Prognosis of Patients with Acute Myeloid Leukemia Regarding the Presence FLT3 Gene Mutation – a Case Report

leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood . 2002;100:2393-2398. 4. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood . 2002;100:2387-2392. 5. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood . 2016;127:62-70. 6. Pefani E, Panoskaltsis N, Mantalaris A, Georgiadis MC

Open access
Watch and Wait – Actualities in the Treatment of Chronic Lymphocytic Leukemia

al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol . 2010;28:1749-1755. 31. Montserrat E, Gribben JG. Autografting CLL: the game is over. Blood . 2011;117:6057-6058. 32. Sutton L, Chevret S, Tournilhac O, et al. Autologous stem cell transplantation as first-line treatment strategy for chronic lymphocytic leukemia: a multicentre, randomized, controlled trial from the SFGM-TC and GFLLC. Blood . 2011;117:6109-6119. 33. Magni M, Di Nicola M, Patti C, et al. Results of a randomized

Open access
Inflammation in Acute Cardiac Care

Atherosclerotic Disease. N Engl J Med. 2017;377:1119-1131. doi: 10.1056/NEJMoa1707914. 12. Gyöngyösi M, Hemetsberger R, Wolbank S, et al. Delayed Recovery of Myocardial Blood Flow After Intracoronary Stem Cell Administration. Stem Cell Review and Reports. 2011;7:616-623. 13. Benedek I, Bucur O, Benedek T. Intracoronary Infusion of Mononuclear Bone Marrow-Derived Stem Cells is Associated with a Lower Plaque Burden After Four Years. J Atheroscler Thromb. 2014;21:217-229. 14. Gyöngyösi M, Hemetsberger R, Posa A, et al. Hypoxia

Open access
Pre-selection of primary intubation technique is associated with a low incidence of difficult intubation in patients with a BMI of 35 kg/m2 or higher


Background: The incidence of difficult intubation (DI) in obese patients may reach a two-digit figure. No studies have assessed the effect of primary use of special intubation devices on lowering the incidence of DI. We assessed the effect of primary selection of special intubation techniques on the incidence of DI in patients with a BMI of 35 kg/m2 or higher. Patients and methods: Data from 546 patients with a BMI of 35 kg/m2 or higher who underwent bariatric surgery at Wolfson Medical Center from 2010 through 2014 was retrospectively extracted and analyzed for demographics, predictors of DI and intubation techniques employed. Difficult intubation was defined as the presence of at least one of the followings: laryngoscopy grade 3 or 4, need for >1 laryngoscopy or intubation attempt, need for changing the blade size, failed direct laryngoscopy (DL), difficult or failed videolaryngoscopy (VL-Glidescope), difficult or failed awake fiberoptic intubation (AFOI) and using VL or awake AFOI as rescue airway techniques. Primary intubation techniques were direct DL, VL and AFOI. We correlated the predictors of DI with the actual incidence of DI and with the choice of intubation technique employed. Results: The overall incidence of DI was 1.6% (1.5% with DL vs. 2.2 with VL + AFOI, p = 0.61). With logistic regression analysis, age was the only significant predictor of DI. Predictors of DI that affected the selection of VL or AFOI as primary intubation tools were Mallampati class 3 or 4, limited neck movement, age, male gender, body mass index and obstructive sleep apnea syndrome. Conclusion: The lower incidence of DI in our study group may stem from the primary use of special intubation devices, based on the presence of predictors of DI.

Open access